Do analysts recommend ATXI or LIMN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, ATXI or LIMN?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avenue Therapeutics N/A N/A -$10.38M -$0.53 N/A Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A

Is ATXI or LIMN more profitable?

Liminatus Pharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% Liminatus Pharma N/A N/A -299.79%

Do analysts prefer RDHL or ATXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is RDHL or ATXI more profitable?

Redhill Biopharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Avenue Therapeutics N/A -471.57% -296.50%

Do analysts recommend ATXI or RNAZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ATXI or RNAZ?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avenue Therapeutics N/A N/A -$10.38M -$0.53 N/A TransCode Therapeutics N/A N/A -$34.66M -$50.33 N/A

Is ATXI or RNAZ more profitable?

Avenue Therapeutics' return on equity of -471.57% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% TransCode Therapeutics N/A -875.35% -50.36%

Do analysts rate GOVX or ATXI?

GeoVax Labs presently has a consensus target price of $150.00, suggesting a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Avenue Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GOVX or ATXI more profitable?

Avenue Therapeutics' return on equity of -471.57% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% Avenue Therapeutics N/A -471.57% -296.50%

Do analysts rate ATXI or SXTP?

60 Degrees Pharmaceuticals has a consensus target price of $13.85, suggesting a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Avenue Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Avenue Therapeutics (ATXI) Competitors

$0.30 0.00 (0.00%)

As of 07/2/2026 02:12 PM Eastern

Compare

ATXI vs. LIMN, RDHL, RNAZ, GOVX, and SXTP

Should you buy Avenue Therapeutics stock or one of its competitors? MarketBeat compares Avenue Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avenue Therapeutics include Liminatus Pharma (LIMN), Redhill Biopharma (RDHL), TransCode Therapeutics (RNAZ), GeoVax Labs (GOVX), and 60 Degrees Pharmaceuticals (SXTP). These companies are all part of the "pharmaceutical products" industry.

How does Avenue Therapeutics compare to Liminatus Pharma?

Avenue Therapeutics (NASDAQ:ATXI) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

In the previous week, Liminatus Pharma had 3 more articles in the media than Avenue Therapeutics. MarketBeat recorded 3 mentions for Liminatus Pharma and 0 mentions for Avenue Therapeutics. Liminatus Pharma's average media sentiment score of 0.64 beat Avenue Therapeutics' score of 0.00 indicating that Liminatus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Liminatus Pharma	Positive

17.3% of Avenue Therapeutics shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Avenue Therapeutics has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 5.62, indicating that its share price is 462% more volatile than the broader market.

Liminatus Pharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Liminatus Pharma	N/A	N/A	-299.79%

Summary

Liminatus Pharma beats Avenue Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Avenue Therapeutics compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Redhill Biopharma has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A

Redhill Biopharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Avenue Therapeutics	N/A	-471.57%	-296.50%

In the previous week, Redhill Biopharma's average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Avenue Therapeutics	Neutral

Redhill Biopharma has a beta of 4.98, meaning that its share price is 398% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market.

Summary

Redhill Biopharma beats Avenue Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to TransCode Therapeutics?

Avenue Therapeutics (NASDAQ:ATXI) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.3% of Avenue Therapeutics shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Avenue Therapeutics has a beta of -0.17, suggesting that its stock price is 117% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

Avenue Therapeutics' return on equity of -471.57% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
TransCode Therapeutics	N/A	-875.35%	-50.36%

In the previous week, TransCode Therapeutics had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for TransCode Therapeutics and 0 mentions for Avenue Therapeutics. Avenue Therapeutics' average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
TransCode Therapeutics	Neutral

Avenue Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A

Summary

Avenue Therapeutics beats TransCode Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

GeoVax Labs has a beta of 3.68, meaning that its stock price is 268% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

In the previous week, GeoVax Labs had 2 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for Avenue Therapeutics. GeoVax Labs' average media sentiment score of 0.49 beat Avenue Therapeutics' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Neutral
Avenue Therapeutics	Neutral

Avenue Therapeutics' return on equity of -471.57% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Avenue Therapeutics has lower revenue, but higher earnings than GeoVax Labs. Avenue Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.66	-$21.47M	-$19.12	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A

GeoVax Labs presently has a consensus target price of $150.00, suggesting a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Avenue Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Avenue Therapeutics beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

How does Avenue Therapeutics compare to 60 Degrees Pharmaceuticals?

Avenue Therapeutics (NASDAQ:ATXI) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

60 Degrees Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A
60 Degrees Pharmaceuticals	$1.41M	3.23	-$7.36M	-$8.92	N/A

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Avenue Therapeutics. 60 Degrees Pharmaceuticals' average media sentiment score of 0.75 beat Avenue Therapeutics' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
60 Degrees Pharmaceuticals	Positive

Avenue Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

60 Degrees Pharmaceuticals has a consensus target price of $13.85, suggesting a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Avenue Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Avenue Therapeutics has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.47, indicating that its share price is 147% more volatile than the broader market.

Summary

60 Degrees Pharmaceuticals beats Avenue Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATXI vs. The Competition

Export

Metric	Avenue Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.01M	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	0.02	1.66	28.02	24.70
Price / Sales	N/A	127.11	540.55	99.42
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	0.16	8.17	10.96	6.46
Net Income	-$10.38M	-$3.71M	$3.57B	$337.01M
7 Day Performance	8.93%	2.59%	2.12%	1.69%
1 Month Performance	-13.48%	4.41%	5.25%	3.81%
1 Year Performance	-10.27%	49.43%	33.29%	23.90%

Avenue Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATXI Avenue Therapeutics	N/A	$0.31 flat	N/A	-10.3%	$1.01M	N/A	0.02	4	Gap Down
LIMN Liminatus Pharma	1.0685 of 5 stars	$0.10 -1.1%	N/A	-98.4%	$4.53M	N/A	N/A	N/A	Gap Up
RDHL Redhill Biopharma	1.3327 of 5 stars	$0.87 -4.3%	N/A	-59.7%	$4.52M	$290K	0.00	210	Positive News Short Interest Decrease Gap Up
RNAZ TransCode Therapeutics	0.1162 of 5 stars	$4.72 -3.5%	N/A	+7.1%	$4.51M	N/A	N/A	9	News Coverage Short Interest Increase
GOVX GeoVax Labs	2.6784 of 5 stars	$1.29 -6.5%	$150.00 +11,527.9%	-90.1%	$4.48M	$2.49M	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATXI) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avenue Therapeutics (ATXI) Competitors

ATXI vs. LIMN, RDHL, RNAZ, GOVX, and SXTP

How does Avenue Therapeutics compare to Liminatus Pharma?

Summary

How does Avenue Therapeutics compare to Redhill Biopharma?

Summary

How does Avenue Therapeutics compare to TransCode Therapeutics?

Summary

How does Avenue Therapeutics compare to GeoVax Labs?

Summary

How does Avenue Therapeutics compare to 60 Degrees Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avenue Therapeutics (ATXI) Competitors

ATXI vs. LIMN, RDHL, RNAZ, GOVX, and SXTP

How does Avenue Therapeutics compare to Liminatus Pharma?

Does the media prefer ATXI or LIMN?

Do insiders and institutionals have more ownership in ATXI or LIMN?

Which has better valuation & earnings, ATXI or LIMN?

Do analysts recommend ATXI or LIMN?

Which has more risk & volatility, ATXI or LIMN?

Is ATXI or LIMN more profitable?

Summary

How does Avenue Therapeutics compare to Redhill Biopharma?

Do analysts prefer RDHL or ATXI?

Do institutionals & insiders have more ownership in RDHL or ATXI?

Which has preferable earnings & valuation, RDHL or ATXI?

Is RDHL or ATXI more profitable?

Does the media favor RDHL or ATXI?

Which has more risk & volatility, RDHL or ATXI?

Summary

How does Avenue Therapeutics compare to TransCode Therapeutics?

Do analysts recommend ATXI or RNAZ?

Do institutionals and insiders have more ownership in ATXI or RNAZ?

Which has more volatility and risk, ATXI or RNAZ?

Is ATXI or RNAZ more profitable?

Does the media refer more to ATXI or RNAZ?

Which has stronger earnings & valuation, ATXI or RNAZ?

Summary

How does Avenue Therapeutics compare to GeoVax Labs?

Do institutionals & insiders believe in GOVX or ATXI?

Which has more volatility and risk, GOVX or ATXI?

Does the media favor GOVX or ATXI?

Is GOVX or ATXI more profitable?

Which has better valuation & earnings, GOVX or ATXI?

Do analysts rate GOVX or ATXI?

Summary

How does Avenue Therapeutics compare to 60 Degrees Pharmaceuticals?

Which has stronger valuation and earnings, ATXI or SXTP?

Does the media refer more to ATXI or SXTP?

Is ATXI or SXTP more profitable?

Do analysts rate ATXI or SXTP?

Do insiders and institutionals believe in ATXI or SXTP?

Which has more risk and volatility, ATXI or SXTP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools